Le Lézard
Classified in: Health
Subject: AWD

Dr. Bruce S. Hoffman is recognized by Continental Who's Who


BROOKLYN, N.Y., Nov. 17, 2017 /PRNewswire/ -- Dr. Bruce S. Hoffman is recognized by Continental Who's Who as a Pinnacle Professional Member in the field of Psychology in recognition of his role as Clinical Psychologist at Bruce S. Hoffman, Psy.D.  

Bruce S. Hoffman is a clinical psychologist and teacher, rated in the top 1% of his field by Rate MD. Dr. Bruce S. Hoffman has been practicing for over twenty years. Dr. Hoffman currently runs his own private practice out of his offices in Brooklyn, New York where he specializes in working with patients with a variety of mental and emotional health conditions, including ADHD, substance abuse, anxiety disorders, depression, PTSD, eating disorders, as well as sleeping disorders. With an international reputation for his groundbreaking work, Dr. Hoffman treats patients from all over the world and has been recognized by Cambridge Who's Who for his Dedication, Leadership, and Excellence in Psychology.

Dr. Hoffman was interested in the mind from a young age, leading him to pursue a career in psychology and how the human thought process works. As he recalls:

"I was interested in Buddhism and Zen at an early age, which led me to believe that thinking is all relative to the person. There are no absolutes. Everything thought originates in our conditioning. From my own upbringing, I realized how powerful and deceiving thought could be, and how the effects of it could keep you moving backward instead of moving forward."

Since receiving his Certification and Doctorate of Science in Psychology from Pace University in 1995, Dr. Hoffman has developed his clinical practice to treat patients of all ages and mental facilities who are experiencing psychological distress from a variety of ailments. He focuses primarily on groundbreaking treatments and on an in-depth diagnosis, demanding his own innovative technique of evaluation and understanding.

Through his unique approach to teaching patients what thought and thinking actually is, Dr. Hoffman strives to help each patient realize that they are the sole creators of their own thoughts and no longer have to be at their mercy. They are given the tools to begin healing themselves. Every treatment plan is configured according to each patient's individual personality and Dr. Hoffman is proud to have a ninety percent success rate with his patients without the use of medication.

As a leader in his specialty, Dr. Hoffman pays close attention to his patients and the world around them in order to help provide them with a real understanding of their thought processes and how to develop greater control over them moving forward. Commenting on his focus on the nature of thought, he notes:

"You don't see any other psychologists really talking about what thought is. They have no idea. It is almost like a dentist performing a root canal on a tooth, yet the dentist knows nothing about what a tooth is or how it functions. It is very validating to see my patients evolve from the state in which they arrived at my door. With the proper guidance, they can enjoy a life full of quality, with full control of their thoughts and emotions."

A member of the American Psychological Association, Dr. Hoffman is also a teacher, focusing on spreading his approach to coping with thoughts and emotions. He speaks at numerous NYC schools regarding thought management and how to avoid letting thoughts take control of your life. He continues to work closely with patients on taking full control of their mind and determining the direction of their own lives.

Contact: Katherine Green, 516-825-5634, [email protected]

SOURCE Continental Who's Who


These press releases may also interest you

at 07:10
Can-Fite BioPharma Ltd. , a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced financial results and clinical updates for the twelve months ended...

at 07:10
Kelonia Therapeutics, a biotech company revolutionizing in vivo gene delivery, today announced the appointments of global leaders in cell therapy and drug development, Kristen Hege, M.D., and Mathai Mammen, M.D., Ph.D., to its board of directors....

at 07:05
Aldeyra Therapeutics, Inc. (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the clinical development plan intended to enable...

at 07:05
Mythic Therapeutics, a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, announced that George Eliades, Ph.D., has joined the...

at 07:05
Seres Therapeutics, Inc. ("Seres" or the "Company"), a leading microbiome therapeutics company, today announced that on March 25, 2024, the Compensation and Talent Committee of Seres' board of directors granted inducement equity grants covering an...

at 07:05
Gilead Sciences, Inc. and Xilio Therapeutics, Inc. today announced an exclusive license agreement to develop and commercialize Xilio's Phase 1 tumor-activated IL-12 program, XTX301. Xilio Therapeutics is a clinical-stage biotechnology company...



News published on and distributed by: